Fudan University

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This study is testing whether giving radiation therapy before surgery can shrink advanced breast tumors that didn't respond well to chemotherapy, making them operable. Researchers are also testing if a dietary supplement called beta-alanine and a special type of radiation (lattic…

This phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women ag…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how s…

This phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…

This study tests whether removing a blood clot from the brain up to 72 hours after a stroke can help patients recover better than standard care. About 336 adults with severe strokes due to a large vessel blockage will be randomly assigned to get the clot removal procedure or usua…

This study is testing whether using an indoor air purifier can improve lung health in people with Chronic Obstructive Pulmonary Disease (COPD). About 120 adults with COPD who live in Shanghai will use either a real air purifier or a placebo device in their homes for a period of t…

This phase 2 trial tests whether a combination of a gonadotropin-releasing hormone agonist (triptorelin) and letrozole can achieve better complete response rates than standard hormone therapy (megestrol acetate or medroxyprogesterone acetate) in women with early-stage endometrial…

This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…

This study tests whether a combination of two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults whose cancer cannot be removed by surgery or radiation will …

This phase 3 trial compares an all-oral drug combination (pyrotinib, trastuzumab, and dalpiciclib) against standard chemotherapy plus targeted drugs for advanced HER2-positive breast cancer. About 502 patients who have had at most one prior treatment will be enrolled. The goal is…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This trial is testing whether giving a combination of radiation, chemotherapy, and an immunotherapy drug before surgery can help people with high-risk soft tissue sarcoma. The study will include 52 adults whose tumors are large or hard to remove. The goal is to see if this approa…

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and possibly other cancer drugs for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumor…

This study is for people with colorectal cancer that came back within a year after finishing initial chemotherapy. It tests whether adding an immunotherapy drug called serplulimab to standard second-line chemo and targeted therapy can help control the cancer longer. About 40 part…

This study tests a new combination of drugs (L-Ornithine L-Aspartate, N-Acetylcysteine, CDK4/6 inhibitors, and Fulvestrant) in 40 women with HR-positive/HER2-negative advanced breast cancer whose disease got worse after standard therapy. The goal is to see if the combo can shrink…

This study tests a mix of three chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy drug (durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it …

This phase 2 trial tests a new drug called vebrekotuzumab, which delivers a powerful toxin directly to cancer cells that have a protein called EGFR. It is being tested alone or with an immunotherapy drug in 104 patients whose esophageal cancer has stopped responding to initial tr…

This study is for people with high-risk stage III colorectal cancer. It tests whether using a blood test (ctDNA) to guide treatment decisions can improve outcomes. Participants will receive either standard chemotherapy or chemotherapy plus bevacizumab, with regular blood monitori…

This study is for people with stage I or low-risk stage II colorectal cancer who have a positive ctDNA blood test one month after surgery, indicating a higher risk of recurrence. Researchers will assign different chemotherapy regimens based on ctDNA results to see if this persona…

This study is for people with high-risk stage II colorectal cancer who have a positive blood test for tumor DNA one month after surgery. It tests whether using that blood test to choose stronger or different chemotherapy can help clear the tumor DNA and prevent the cancer from co…

This study tests a treatment plan for people with low rectal cancer that can be removed with surgery. Participants receive chemotherapy and an immunotherapy drug called tislelizumab before surgery. The goal is to see if this combination can make the cancer disappear completely, a…

This study tests whether using a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with stage II or low-risk stage III colorectal cancer will be randomly assigned to sta…

This study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus r…

This study tests whether adding an immunotherapy drug (anti-PD-1) to standard chemoradiation can better control anal squamous cell cancer and reduce the chance of it coming back. It includes 241 adults aged 18-75 with different stages of the disease, from early to advanced or rec…

This phase 3 trial tests whether adding chemotherapy to standard radiation after thymic cancer surgery can prevent the cancer from coming back. About 172 adults who had complete tumor removal will receive either radiation alone or radiation plus four cycles of chemotherapy (pacli…

This study looks at whether giving radiation therapy after complete surgical removal of stage II or III thymoma helps prevent the cancer from returning. About 238 adults aged 18 to 75 who had their tumor fully removed will be randomly assigned to receive either radiation or no ad…

This Phase 2 trial is testing whether adding a targeted chemotherapy infusion into the liver (HAIC) to a combination of two drugs—sintilimab (an immunotherapy) and bevacizumab biosimilar (which blocks blood vessel growth)—helps people with advanced liver cancer live longer withou…

This study tests several new drug combinations for people with advanced liver cancer whose first treatment stopped working. It involves 350 adults and uses advanced imaging and genetic tests to find which treatment works best for each person. The goal is to shrink or control the …

This study tests whether adding the drug cadonilimab (AK104) and radiation to standard chemotherapy helps people with colorectal cancer that has spread to the liver. About 73 adults who have not had treatment before will be randomly assigned to either the new combo or standard th…

This study is observing 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers will track how well different drug combinations shrink tumors and how the immune system changes. The goal is to learn which treatments work best and why, w…

This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.

This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esoph…

This study tests whether giving treatments based on the genetic makeup of a person's triple-negative breast cancer can shrink tumors or slow the disease. It is for people whose cancer has not responded to standard therapies. About 120 women will receive a treatment chosen specifi…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This study is for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer often linked to EBV. It compares three different sequences of chemotherapy, immunotherapy, and radiation to see which one keeps the cancer from coming back for at least two year…

This study tests whether adding radiotherapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (Toripalimab) can improve outcomes for people with a specific type of locally advanced rectal cancer (MSS/pMMR). About 192 participants will receive either the drug com…

This early-phase study tests whether specially engineered immune cells (CAR-T and TCR-T) can safely fight Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma that has returned or not responded to treatment. About 24 adults will receive one of two types of cell therapy, wit…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. About 51 adults aged 18 to 75 will receive the drug combination. The goal is to …

This study tests a chemotherapy regimen (R-CDOP) plus a drug injected into the spine (intrathecal methotrexate) in 83 adults with untreated diffuse large B-cell lymphoma at high risk of spreading to the brain. The goal is to see if this combination lowers the chance of central ne…

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will tak…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach or gastroesophageal junction cancer from coming back after surgery. It includes 276 adults with high-risk or specific genetic types of cancer. Participants ar…

This early study tests a new cell therapy called RGL-305 in 12 lymphoma patients who still have traces of cancer after standard treatment. The therapy is given through an IV over several cycles. The main goal is to check if it is safe and how the cells behave in the body, not yet…

This phase 2 trial tests two oral drugs, SHR-0302 and SHR-2554, in about 25 people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The drugs work by blocking specific proteins that help cancer grow. The study aims to see if the combination …

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific, hard-to-treat form of advanced triple-negative breast cancer (called BLIS subtype). About 134 participants who have not had prior treatment for metastatic …

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This study aims to improve fertility-sparing treatment for young women (ages 18-45) with endometrial cancer by tailoring therapy to the tumor's genetic profile. Participants will receive either hormone therapy (progestins) or a combination with an immunotherapy drug (sintilimab),…

This study tests whether adding precise radiation (SBRT) to a four-drug combination (sintilimab, bevacizumab, and chemotherapy) can help people with advanced EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy. About 53 participants will rece…

This phase 3 trial is testing whether giving radiation only to the lower armpit lymph nodes works as well as giving radiation to a larger area of lymph nodes in breast cancer patients who have 1-2 positive sentinel nodes. The study plans to enroll 1608 women with early-stage brea…

This study tests a drug called tunlametinib in people with advanced melanoma that has a specific NRAS gene change and has not responded to prior immunotherapy. About 110 adults will take the drug by mouth to see if it can shrink tumors and how safe it is. The goal is to control t…

This study looks at whether giving radiation therapy within 6 weeks after surgery can help prevent thyroid cancer from coming back in people at high risk. It includes 80 patients with various types of thyroid cancer (except undifferentiated). The main goal is to see how long they…

This study looks at whether adding radiation therapy to the usual radioactive iodine treatment can help prevent thyroid cancer from coming back in people with high-risk, advanced thyroid cancer. About 124 adults who had surgery but still have some cancer left will be randomly ass…

This study tests whether a smaller, more targeted neck surgery (selective neck dissection) works as well as the standard larger surgery (modified neck dissection) for people with papillary thyroid cancer that has spread to only 1 or 2 small lymph nodes in the side of the neck. Ab…

This study tests whether adding probiotics (good bacteria) to standard chemoradiation and immunotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 60 adults aged 18-80 will take part. The goal is to see if this c…

This study tests whether a new drug, serplulimab, combined with chemotherapy works better than the standard drug, nivolumab, plus chemotherapy for shrinking lung cancer before surgery. About 116 people with stage II to IIIa squamous non-small cell lung cancer will take part. The …

This study tests whether metformin, a diabetes drug, can improve memory and thinking in overweight adults aged 60-75 with mild cognitive impairment. Half of the 54 participants will take metformin daily for 26 weeks, while the other half will receive lifestyle advice only. Resear…

This study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune check…

This study tests whether a blood test that tracks tumor DNA (ctDNA) can help doctors decide when to intensify treatment for HER2-negative metastatic breast cancer. All 122 participants start with antibody-drug conjugate (ADC) therapy. After two cycles, those whose disease hasn't …

This study tests whether a transplant of donated umbilical cord blood can help people aged 14 to 80 with serious diseases caused by the Epstein-Barr virus (EBV), such as certain lymphomas or chronic active EBV infection. The goal is to control the disease and improve survival, bu…

This study tests a new surgical technique called Q-ISR for people with ultra-low rectal cancer. It compares Q-ISR to two standard surgeries to see if it can better preserve bowel function while still controlling the cancer. About 100 adults with small tumors near the anal opening…

This phase 2 trial tests whether adding IL-11 to the standard drug G-CSF helps blood cells recover faster after a stem cell transplant in people with multiple myeloma or lymphoma. About 224 adults will receive either the combination or G-CSF alone before their transplant. The goa…

This study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from coming back in high-risk patients with HR+/HER2+ early breast cancer. About 1,900 women aged 18-70 who have already completed anti-HER2 therapy will be randomly assi…

This phase 3 trial tests whether adding an anti-vascular drug to standard chemotherapy can help prevent cancer from returning in people with a specific, aggressive type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combinati…

This study tests a combination of two drugs, fruquintinib and serplulimab, in people with advanced colorectal cancer that has spread to places other than just the liver and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow …

This phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can …

This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …

This study tests new drug combinations (ADC drugs alone or with other therapies) in 160 people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to find safe doses and see if tumors shrink. Participants must be 18-75, in good overall health, and ha…

This study tests whether adding immunotherapy to a precise type of radiotherapy (sparing tumor-draining lymph nodes) and chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the comb…

This study tests whether giving radiation only to the parts of the neck where cancer has spread works as well as treating the entire neck in people with nasopharyngeal carcinoma. About 462 adults with stage I–III disease will be randomly assigned to receive either standard or ind…

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations and has not been treated before. The goal is to see if the drug can shrink tumors and how safe it is. Participants take either 200mg o…

This study tests whether adding omega-3 fatty acids (EPA and DHA) to standard PD-1 inhibitor therapy helps patients with advanced esophageal cancer. About 142 adults will receive either omega-3 or placebo drops daily for 6 months alongside their cancer treatment. The main goal is…

This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participa…

This study is for people with HER2-negative breast cancer that has spread to the lining of the brain (leptomeningeal metastasis). It compares standard chemotherapy given through the veins or by mouth to the same treatment plus extra chemotherapy delivered directly into the spinal…

This study tests a two-step approach for people with liver metastases from triple-negative breast cancer, melanoma, or colorectal cancer. First, doctors use heat or cold to destroy some liver tumors, which may release cancer signals that train the immune system. Then, patients re…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This phase II trial tests a combination of two drugs—MRG003 and pucotenlimab—in 60 people with a rare and aggressive form of thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the d…

This study tests a quality improvement program called 'ICU-NO CRBSI' to prevent catheter-related bloodstream infections in intensive care units. Over 8,000 patients across multiple hospitals in China will receive either standard care or an enhanced evidence-based infection preven…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …

This phase 2 trial is testing a powerful mix of radiation, chemotherapy, immunotherapy, and targeted therapy in 44 patients with locally recurrent rectal cancer that has not responded to prior treatment. The goal is to shrink tumors and enable surgery. Researchers are measuring h…

This phase 2 trial tests a combination of two drugs, SKB264 and inetetamab, in 48 adults with HER2-positive advanced breast cancer that has worsened after prior treatment with T-DXd. The goal is to see if the combo can shrink tumors. Participants receive the drugs intravenously e…

This phase II trial tests whether adding immunotherapy and a COX-2 inhibitor to standard chemoradiotherapy can improve complete remission rates in people with locally advanced rectal cancer that is microsatellite stable (MSS). About 138 participants will receive either long-cours…

This Phase 2 trial is testing an experimental immunotherapy drug called QL1706 combined with standard chemotherapy (nab-paclitaxel and gemcitabine), with or without the targeted drug bevacizumab, as a first treatment for people with advanced pancreatic cancer that cannot be remov…

This phase II trial tests whether adding an immunotherapy drug (serplulimab) and a COX-2 inhibitor (celecoxib) to standard chemoradiotherapy can improve outcomes for people with locally advanced rectal cancer. 138 participants will receive either long-course or short-course radia…

This study looks at whether artificial intelligence can help detect breast cancer using standard chest CT scans that don't require a special dye. Researchers will compare the AI's accuracy to mammograms and breast MRIs in 5,000 women. The goal is to see if this approach could off…

This study is testing a new blood-based diagnostic that looks at tiny particles from breast cancer cells to determine the cancer's molecular subtype. Researchers will compare results from this test with standard tissue biopsies in 1,500 people with advanced breast cancer. If accu…

This study is testing a new blood test that looks at fragments of DNA to find pancreatic neuroendocrine tumors early and tell them apart from other pancreatic tumors. Researchers will collect blood from 1,000 adults with different types of pancreatic tumors to see how accurate th…

This study is testing whether a new type of PET scan (TROP2-PET) can predict how well certain targeted drugs work in people with advanced HER2-negative breast cancer. The drugs, called antibody-drug conjugates, deliver chemotherapy directly to cancer cells. The study will enroll …

This study is testing a new way to screen for stomach cancer using a stool sample and a simple questionnaire. Researchers will enroll 15,000 people aged 40 and older to see if the fecal DNA test can find cancer earlier than current methods. Participants will provide a stool sampl…

This study is testing a new, non-invasive stool test that looks for specific gene changes in H. pylori bacteria linked to stomach cancer. Researchers will compare the test's accuracy with a standard risk questionnaire in 15,000 adults aged 40 and older. The goal is to see if this…

This study is testing whether AI-assisted ultrasound and mammography can improve breast cancer screening compared to standard methods. About 16,000 women aged 35-69 will be split into two groups: one gets AI-assisted imaging, the other gets routine screening. The goal is to see i…

This study looks at whether a small tissue sample taken during an endoscopy (biopsy) can give the same information about gastric cancer as a larger sample taken during surgery. Researchers will compare results from 510 patients to see if the biopsy is just as accurate for key can…

This study tests whether a blood test that looks for tumor DNA (ctDNA) can detect colorectal cancer recurrence earlier than usual methods like CT scans and CEA blood tests. About 584 people with stage I-III colorectal cancer who had surgery will be randomly assigned to either sta…

This study tests a cream called Pinoxin to see if it can prevent skin injuries caused by radiation therapy in cancer patients. About 202 adults receiving high-dose radiation will be randomly assigned to use either Pinoxin or a placebo cream. The main goal is to see if Pinoxin low…

This study tests whether limiting eating to a 10-hour window each day can lower the chance of developing gestational diabetes in pregnant women at high risk. Researchers will compare this approach to usual eating habits over 3 months in 240 women. The goal is to see if this simpl…

This study tests whether wearing compression or ice gloves and socks can reduce nerve damage caused by the chemotherapy drug UTD1 in women with advanced breast cancer. 324 participants will be randomly assigned to wear nothing, compression gloves/socks, or ice gloves/socks during…

This study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…

This study tests a digital mind-body therapy that uses music and biofeedback to help women with advanced breast cancer who are undergoing chemotherapy before surgery. The goal is to see if it can reduce sleep problems, anxiety, and depression. Sixty-six participants will be rando…

This phase 3 trial is testing whether the corticosteroid dexamethasone can reduce hand-foot syndrome—a painful skin reaction—caused by liposomal doxorubicin chemotherapy in breast cancer patients. 182 participants will receive either high-dose, standard-dose, or no dexamethasone …

This study tests whether a personalized comfort care plan can help people with advanced esophageal cancer live longer and feel better. About 624 adults whose cancer has spread or returned will receive either standard comfort care or a tailored version that adjusts to their needs.…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study looks at breast cancer that has spread to the brain. Researchers want to understand how much of the drug trastuzumab deruxtecan gets into the fluid around the brain and spinal cord, and whether that amount relates to how well the drug shrinks brain tumors. About 60 adu…

This study will follow 1 million Chinese adults with cancer to measure how common and severe cancer-related fatigue is. Researchers will look at what factors influence fatigue and how it affects treatment and survival. The goal is to better understand this common but often overlo…

This study looks at how different lung cancer screening habits (like too much, too little, or just right) affect whether the cancer is caught early. About 5,390 newly diagnosed lung cancer patients will share their medical history and screening records. The goal is to find the be…

This study is creating a large database of 1,000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long patients live and how long their cancer stays under control. The goal is to learn which treatments work best for differen…

This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…

This study will follow 3000 people in China with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Researchers will track which treatments patients actually receive and how they fare, aiming to build better prediction tools and understand why some patients relapse. …

This study follows 3,000 adults aged 40 and older who carry Helicobacter pylori, a common stomach bug. Researchers want to see if people with certain high-risk subtypes of the bacteria develop stomach cancer more often than those with other subtypes or no infection. Participants …

This study aims to understand which types of HPV are linked to anal cancer in China and how common the disease is. Researchers will collect samples and health data from 300 patients across multiple hospitals. The goal is to learn more about the virus and disease patterns, not to …

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to fi…

This study looks at how blood components differ between younger and older women with a common type of breast cancer (HR+HER2-). Researchers will collect blood and tumor samples before and during treatment to find age-related markers that might predict how well the therapy works. …

This study looks at how the pain and sedation drug remifentanil behaves in low-weight patients in the intensive care unit who are on breathing machines. Researchers will measure drug levels in the blood and check vital signs like blood pressure. The goal is to find the right dose…

This study looks at whether a person's mental state—like anxiety or depression—can influence how well immunotherapy works for triple-negative breast cancer. About 120 women will receive standard treatment, complete psychological surveys, and give blood and saliva samples. Researc…

This study is looking at whether a blood test that detects tiny bits of tumor DNA (called ctDNA) can help doctors more accurately assess how well treatment is working and predict if cancer will come back in people with advanced colorectal cancer. About 497 participants who are re…

This study will follow 1,000 adults who come to fever clinics with a respiratory infection. Researchers will collect data on symptoms, lab tests, and chest scans at the start, then check in over time to see who develops pneumonia or other complications. The goal is to better unde…

This study compares three types of anesthesia during colorectal cancer surgery: opioid-based, opioid-sparing, and opioid-free. Researchers will measure immune markers called NETs in the blood and test how the blood affects cancer cells in the lab. The goal is to see if avoiding o…

This study will follow 2,500 people newly diagnosed with marginal zone B-cell lymphoma to better understand the disease and how different treatments affect it. Researchers will track how long patients live without the cancer getting worse and how well various therapies work. The …

This study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…

This observational study aims to understand how ROS1-positive non-small cell lung cancer develops resistance to the drug entrectinib. Researchers will analyze blood and tissue samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at…

This study is creating a large, real-world database for a rare pancreatic tumor called solid pseudopapillary neoplasm (SPN). Researchers will collect data from 2,000 participants to track long-term outcomes like survival and recurrence. The goal is to provide high-quality evidenc…

This study follows 1,100 people with esophageal cancer to see how often the cancer spreads to a specific lymph node near the windpipe (subcarinal node). Researchers will also look for factors that make spread more likely. The goal is to help doctors decide whether to remove these…

This study observes 1,852 people with esophageal cancer to see how often the cancer spreads to a specific lymph node in the chest (left tracheobronchial lymph node). Researchers will track who develops this spread and look for risk factors. The goal is to better understand the di…